# A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

> **NCT03701555** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 139 (actual)

## Conditions studied

- Digestive System Disease

## Interventions

- **OTHER:** PvP001 placebo
- **DRUG:** PvP001 100 mg
- **DRUG:** PvP001 300 mg
- **DRUG:** PvP001 900 mg
- **DRUG:** Maximum Feasible Dose (MFD) of PvP002
- **DRUG:** Maximum Tolerated Dose (MTD) of PvP001
- **DRUG:** MTD of PvP001 following 7 days of PPI treatment
- **OTHER:** PvP002 placebo
- **DRUG:** PvP001 600 mg
- **DRUG:** PvP003 placebo
- **DRUG:** PvP003
- **DRUG:** PvP003 150 mg

## Key facts

- **NCT ID:** NCT03701555
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-07-02
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03701555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03701555, "A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03701555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*